Eli Lilly (LLY) – Among the 10 Safe Stocks to Buy for the Long Term in 2026

Eli Lilly and Company (NYSE:LLY) is included among the 10 Safe Stocks to Buy for the Long Term in 2026.

Eli Lilly (LLY) - Among the 10 Safe Stocks to Buy for the Long Term in 2026

On May 26, BofA raised the firm’s price recommendation for Eli Lilly and Company (NYSE:LLY) to $1,251 from $1,133. It reiterated a Buy rating on the shares. The firm said it expects Lilly’s future revenue and profit growth to be driven by a doubling of GLP-1 U.S. market sales by 2033, the analyst told investors.

In separate news, Reuters reported on May 21 that Eli Lilly said its experimental obesity drug helped patients lose more than 28% of their weight over an 18-month period in a key clinical trial. The results could allow the company to seek regulatory approval and potentially launch the next-generation treatment next year.

The results were largely in line with Wall Street expectations and could position retatrutide as one of the most powerful weight-loss drugs in the growing obesity treatment market, where Lilly competes with Novo Nordisk.

Eli Lilly and Company (NYSE:LLY) is a medicine company that discovers, develops, manufactures, and markets pharmaceutical products through a single business segment focused on human pharmaceuticals.

While we acknowledge the risk and potential of LLY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than LLY and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: Dividend Stock Portfolio For Retirement: Top 12 Stock Picks and 10 Best June Dividend Stocks to Buy

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1